Despite having seven employees who all work from home, FerroKin Biosciences plans to bring a drug to market in 2015, reports The Atlantic's Quinn Norton. This low overhead model, Norton adds, allows the companies to focus on nice drugs, and the one FerroKin is developing is to treat congenital anemias.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.